STOCK TITAN

GE HealthCare Technologies (GEHC) Stock Price, News & Analysis

GEHC NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
7 252 sessions, November 19, 2025 to November 19, 2026
Largest daily move
-13.2% close of April 29, 2026
1-year change
+13.2% closing prices, November 19, 2025 to November 19, 2026
1-month change
+17.4% closing prices, October 19, 2026 to November 19, 2026

Company Description

GE HealthCare Technologies Inc. (Nasdaq: GEHC) is a global healthcare solutions provider operating in the medical technology and pharmaceutical diagnostics space. According to the company, it focuses on innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. GE HealthCare states that it aims to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier, while simplifying the patient journey across care pathways.

GE HealthCare operates through four primary businesses: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. Together, these businesses support patient care from screening and diagnosis to therapy and monitoring, reflecting the company’s focus on the full continuum of care. In industry classifications, GE HealthCare is associated with irradiation apparatus manufacturing within the broader manufacturing sector, which aligns with its activities in diagnostic imaging and related technologies.

The company describes itself as a trusted partner to hospitals and health systems and notes that it has been serving patients and providers for more than 125 years. Over this period, GE HealthCare highlights a heritage at the intersection of medicine and technology, particularly in medical imaging. It emphasizes that its portfolio includes medical technology devices, pharmaceutical diagnostic products, and digital and AI-enabled solutions that support more personalized, connected and compassionate care.

GE HealthCare reports that it is a global healthcare solutions provider, with activities that include collaborations with public and private healthcare systems and academic institutions. For example, the company has announced agreements to supply advanced CT scanners to public hospitals in Indonesia under a national program, and it has described multi-year alliances with healthcare systems such as the University of Rochester Medical Center to support advanced diagnostic imaging, radiopharmaceutical tracer production, and standardized patient monitoring across health systems. These examples illustrate how GE HealthCare positions its technologies within broader healthcare ecosystems.

In addition to imaging hardware and patient monitoring systems, GE HealthCare highlights its work in AI-enabled and cloud-first solutions. The company describes integrating AI, data analytics, and cloud-based platforms into its devices and workflows to support more efficient clinical operations and more precise diagnostic and therapeutic decisions. It has referenced AI-powered tools in areas such as mammography image reconstruction, cardiovascular ultrasound, and radiology workflow software, as well as collaborations that explore automation and autonomous imaging concepts.

GE HealthCare also notes that it develops and supplies pharmaceutical diagnostics, including radiopharmaceutical agents used in imaging. In its public communications, the company links these diagnostics with its imaging systems to support precision medicine approaches, such as molecular imaging and theranostics programs in oncology and cardiology. This combination of devices, diagnostics, and digital tools is presented as central to its approach to advancing precision care.

The company has indicated that it invests substantially in research and development to support new technologies across disease states and care pathways. It has publicly referenced multi-billion-dollar R&D investment over recent years to drive what it calls an innovation renaissance in areas such as CT, MRI, ultrasound, mammography, radiopharmaceuticals, and AI-enabled software. GE HealthCare also points to strategic collaborations with organizations including academic medical centers and technology companies to accelerate development in fields like radiation therapy, oncology, and radiology workflow.

According to its own descriptions, GE HealthCare employs tens of thousands of colleagues worldwide and generates annual revenue in the tens of billions of dollars. The company emphasizes that its workforce and scale are focused on creating what it describes as a world where healthcare has no limits, and it highlights recognition such as being named among Fortune’s World’s Most Admired Companies as an indicator of its standing in the healthcare industry.

From a capital markets perspective, GE HealthCare Technologies Inc. is a Delaware corporation with its common stock listed on Nasdaq under the symbol GEHC. The company files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Forms 10-K, 10-Q, and 8-K. Recent 8-K filings describe, among other matters, the issuance of senior notes and entry into a senior unsecured term loan credit facility, as well as the use of proceeds in connection with an announced acquisition. These filings provide additional detail on the company’s financial obligations and capital structure.

GE HealthCare’s public disclosures also reference its role in supporting health systems in areas such as early diagnosis of non-communicable diseases, expansion of diagnostic access, and development of training and innovation hubs. The company has described initiatives such as regional innovation and training centers and collaborations aimed at capacity building and knowledge transfer, which it associates with strengthening local healthcare ecosystems.

Business Segments and Activities

GE HealthCare identifies four main business areas:

  • Imaging – focused on medical imaging technologies used for screening, diagnosis, and guidance across a range of clinical applications.
  • Advanced Visualization Solutions – software and related technologies that support image interpretation, workflow, and clinical decision-making.
  • Patient Care Solutions – technologies that support patient monitoring and care across various care settings.
  • Pharmaceutical Diagnostics – diagnostic agents, including radiopharmaceuticals, used in imaging to support precision diagnosis and treatment planning.

These businesses are described by the company as working together to improve patient care from initial screening and diagnosis through therapy and ongoing monitoring.

Industry and Sector Context

Within industry classifications, GE HealthCare is associated with irradiation apparatus manufacturing, reflecting its involvement in medical imaging and related technologies. More broadly, it operates in the manufacturing sector with a focus on healthcare. The company’s communications emphasize that its technologies and diagnostics are used in hospitals, health systems, and clinical practices worldwide to support radiology, oncology, cardiology, and other clinical disciplines.

Capital Structure and Regulatory Filings

GE HealthCare’s SEC filings indicate that it is an SEC-registered issuer with a Commission File Number of 001-41528 and that it is incorporated in Delaware. In a recent Form 8-K, the company reported entering into a three-year senior unsecured term loan credit facility and issuing senior notes due in 2028 and 2035. The company stated that it intends to use the net proceeds from these financings, together with cash on hand, to pay the purchase price of a previously announced acquisition of Intelerad Medical Systems. Other 8-K filings have reported quarterly financial results and changes in board composition.

Recognition

GE HealthCare has stated that it is proud to be among Fortune’s World’s Most Admired Companies. The company presents this recognition as consistent with its long history in medical technology and its focus on advancing personalized, connected, and compassionate care.

Stock Performance

$81.55
-0.42%
-0.34
After hoursChange vs the $81.89 closeLast updated: at
+13.2%
Performance 1 year
$36.9B

GE HealthCare Technologies (GEHC) closed at $81.89 on November 19, 2026. Over the past 12 months, the price has gained 13.2%.

See what a $1,000 investment in GEHC would be worth today

Average down calculator for GEHC

GEHC Metrics & Rankings

Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

GE HealthCare Technologies has 10 recent news articles, with the latest published on . Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include clinical trial, AI, earnings. View all GEHC news →

Financial Highlights

GE HealthCare Technologies generated $20.6B in revenue in FY2025, retaining a 40.0% gross margin, operating income reached $2.8B (13.4% operating margin), and net income was $2.1B, reflecting a 10.1% net profit margin. Diluted earnings per share stood at $4.55. The company generated $2.0B in operating cash flow. The current ratio was 1.37, measuring current assets divided by current liabilities.

$20.6B
Revenue (FY2025)
$2.1B
Net Income (FY2025)
$2.0B
Operating Cash Flow

Upcoming Events

NOV
29
November 29, 2026 - December 3, 2026 Marketing

RSNA 2026 demo

GE HealthCare and Intelerad will demonstrate AW ONE integration at RSNA 2026 Annual Meeting; booth and webcast details TBD.
DEC
01
December 1, 2026 Clinical

RSNA presentation

Presentation of preliminary Phase 2 LUMINA results at RSNA annual meeting in Chicago on Dec 1; GE HealthCare presenting; no webcast listed.
H1
2027
H1 2027 Corporate

SOFIE acquisition close

Expected close of GE HealthCare's acquisition of SOFIE Biosciences; subject to regulatory approvals and other closing conditions.
JAN
04
January 4, 2027 Corporate

Board appointment

Pascal Desroches will join GE HealthCare's Board of Directors effective 2027-01-04; brings CFO experience from AT&T and governance background.
YEAR
2028
2028 Operations

CT installation completion

Multi‑year SIHREN program to install 300+ CT scanners across 38 provinces; target complete by 2028

GE HealthCare Technologies has 5 upcoming scheduled events. The next event, "RSNA 2026 demo", is scheduled for November 29, 2026 (in 10 days). Investors can track these dates to stay informed about potential catalysts that may affect the GEHC stock price.

Short Interest History

Last 12 Months

Short interest in GE HealthCare Technologies (GEHC) currently stands at 18.3 million shares, down 5.8% from the previous reporting period, representing 4.1% of the float. Since November 2025, short interest has increased by 63.9%.

Days to Cover History

Last 12 Months

Days to cover for GE HealthCare Technologies (GEHC) currently stands at 4.9 days, down 5.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 123.4%. Across the settlements charted above, it has ranged from 2.0 to 7.5 days.

GEHC Company Profile & Sector Positioning

GE HealthCare Technologies (GEHC) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ. Among dividend-paying stocks, GEHC ranks #2,013 by dividend yield.

Investors comparing GEHC often look at related companies in the same sector, including DexCom, Inc. (DXCM), Koninklijke Philips N.V. (PHG), Edwards Lifesciences Corp (EW), STERIS plc (STE), and Boston Scientific Corporation (BSX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate GEHC's relative position within its industry.

Frequently Asked Questions

The current stock price of GE HealthCare Technologies (GEHC) is $81.55 in after-hours trading as of November 19, 2026.

The market cap of GE HealthCare Technologies (GEHC) is approximately $36.9B. Learn more about what market capitalization means .

The FY2025 revenue of GE HealthCare Technologies (GEHC) is $20.6B, from its most recent completed fiscal year.

The FY2025 net income of GE HealthCare Technologies (GEHC) is $2.1B, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of GE HealthCare Technologies (GEHC) is $4.55 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of GE HealthCare Technologies (GEHC) is $2.0B for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of GE HealthCare Technologies (GEHC) is 10.1% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of GE HealthCare Technologies (GEHC) is 13.4% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of GE HealthCare Technologies (GEHC) is 40.0% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of GE HealthCare Technologies (GEHC), current assets divided by current liabilities, was 1.37 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of GE HealthCare Technologies (GEHC) is $8.2B for FY2025, its most recent completed fiscal year.

The operating income of GE HealthCare Technologies (GEHC) is $2.8B for FY2025, its most recent completed fiscal year. Learn about operating income.

GE HealthCare Technologies Inc. is a global healthcare solutions provider that focuses on medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. The company states that its offerings support care from screening and diagnosis through therapy and monitoring.

GE HealthCare is associated with the irradiation apparatus manufacturing industry within the broader manufacturing sector, reflecting its activities in medical imaging and related healthcare technologies.

According to the company, GE HealthCare’s businesses include Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. These areas are described as working together to help improve patient care across the care pathway.

GE HealthCare reports that it develops integrated, cloud-first AI-enabled solutions and data analytics. It has highlighted AI-powered tools and cloud-based platforms that are intended to support more efficient clinical workflows and more precise diagnostic and therapeutic decisions.

Pharmaceutical Diagnostics is one of GE HealthCare’s four businesses. The company describes it as providing diagnostic agents, including radiopharmaceuticals, that are used with imaging systems to support precision diagnosis, treatment planning, and theranostics programs.

GE HealthCare Technologies Inc. common stock trades on Nasdaq under the ticker symbol GEHC, as referenced in the company’s news releases and SEC filings.

SEC filings list GE HealthCare Technologies Inc.’s principal offices in Chicago, Illinois. The company is incorporated in Delaware and files reports with the U.S. Securities and Exchange Commission.

GE HealthCare states that it has been serving patients and providers for more than 125 years and highlights a long history at the intersection of medicine and technology, especially in medical imaging.

In a recent Form 8-K, GE HealthCare reported entering into a three-year senior unsecured term loan credit facility and issuing senior notes due 2028 and 2035. The company indicated that it intends to use the proceeds, together with cash on hand, to fund the purchase price of a previously announced acquisition of Intelerad Medical Systems.

Yes. Public announcements describe collaborations with organizations such as Indonesia’s Ministry of Health, the University of Rochester Medical Center, and Mayo Clinic, as well as technology partners. These collaborations focus on areas like expanding access to diagnostic imaging, building care alliances, and advancing radiation therapy and cancer care.